COLO.B.DK

635

-1.21%↓

GMAB.DK

1,388.5

-0.47%↓

ZEAL.DK

453.5

-0.46%↓

AMBUB.DK

101.3

-0.78%↓

COLO.B.DK

635

-1.21%↓

GMAB.DK

1,388.5

-0.47%↓

ZEAL.DK

453.5

-0.46%↓

AMBUB.DK

101.3

-0.78%↓

COLO.B.DK

635

-1.21%↓

GMAB.DK

1,388.5

-0.47%↓

ZEAL.DK

453.5

-0.46%↓

AMBUB.DK

101.3

-0.78%↓

COLO.B.DK

635

-1.21%↓

GMAB.DK

1,388.5

-0.47%↓

ZEAL.DK

453.5

-0.46%↓

AMBUB.DK

101.3

-0.78%↓

COLO.B.DK

635

-1.21%↓

GMAB.DK

1,388.5

-0.47%↓

ZEAL.DK

453.5

-0.46%↓

AMBUB.DK

101.3

-0.78%↓

Search

Novo Nordisk A-S (Class B)

Fermé

455.9 -2.2

Résumé

Variation du prix de l'action

24h

Actuel

Min

454.35

Max

460.8

Chiffres clés

By Trading Economics

Revenu

804M

29B

Ventes

-7.6B

78B

P/E

Moyenne du Secteur

19.604

53.54

BPA

6.53

Rendement du dividende

3.57

Marge bénéficiaire

37.182

Employés

77,406

EBITDA

4.1B

39B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.57%

2.44%

Prochains Résultats

6 août 2025

Date du Prochain Dividende

18 août 2025

Date du Prochain Détachement de Dividende

14 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

22B

2T

Ouverture précédente

458.1

Clôture précédente

455.9

Novo Nordisk A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 mai 2025, 11:36 UTC

Actualités

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mai 2025, 09:36 UTC

Principaux Mouvements du Marché

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mai 2025, 11:29 UTC

Actualités
Résultats
Principaux Mouvements du Marché

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 mai 2025, 07:05 UTC

Résultats

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 mai 2025, 06:19 UTC

Résultats

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

29 mai 2025, 01:00 UTC

Actualités

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 mai 2025, 14:08 UTC

Résultats

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 mai 2025, 18:35 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 17:34 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mai 2025, 13:42 UTC

Actions en Tendance

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mai 2025, 13:15 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mai 2025, 12:17 UTC

Résultats

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mai 2025, 15:13 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mai 2025, 13:56 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 13:45 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mai 2025, 11:25 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mai 2025, 11:18 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:55 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 mai 2025, 09:36 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 mai 2025, 09:04 UTC

Résultats
Actions en Tendance

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 mai 2025, 08:10 UTC

Market Talk

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 mai 2025, 08:08 UTC

Market Talk

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 mai 2025, 07:11 UTC

Market Talk
Résultats

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7 mai 2025, 05:39 UTC

Résultats

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

Comparaison

Variation de prix

Novo Nordisk A-S (Class B) prévision

Objectif de Prix

By TipRanks

9.53% hausse

Prévisions sur 12 Mois

Moyen 1,162.73 DKK  9.53%

Haut 1,550 DKK

Bas 720 DKK

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

2

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.